Portfolio

deepull receives FDA Breakthrough Device Designation for its UllCORE Bloodstream Infection Test

December 2, 2024

deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced today that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its UllCORE Bloodstream Infection (BSI) Test.

 

Read more